Search - tctmd.com

Displaying 201 - 211 of 211

Sort: Relevancy | Date

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

News Conference News ACC 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

March 10, 2017

‘Misalignment’ Exists Between What Concerns Patients and Physicians Most After PCI

News Daily News

‘Misalignment’ Exists Between What Concerns Patients and Physicians Most After PCI

Michael O'Riordan

February 13, 2017

Rivaroxaban’s “Overwhelming” Efficacy for Coronary, Peripheral Disease Leads to Early Halt of COMPASS

News Daily News

Rivaroxaban’s ‘Overwhelming’ Efficacy for Coronary, Peripheral Disease Leads to Early Halt of COMPASS

February 08, 2017

How Low Can Cholesterol Go? Safety Not in Limbo for Patients With Very Low LDL on Alirocumab, Study Shows

News Daily News

How Low Can Cholesterol Go? Safety Not in Limbo for Patients With Very Low LDL on Alirocumab, Study Shows

Yael L. Maxwell

January 31, 2017

News Features

Coalition of the Willing: PERTs Aim to Disentangle ‘Gordian Knot’ of Acute Pulmonary Embolism

January 02, 2017

News Conference News AHA 2016

Ticagrelor Fails to Best Clopidogrel in Preventing CV Events in PAD Patients

Yael L. Maxwell

November 13, 2016

News Daily News

Semaglutide Cuts Risk of Major Cardiovascular Events in Type 2 Diabetes: SUSTAIN-6

Michael O'Riordan

September 16, 2016

News Conference News ESC 2016

Focus on LDL Cholesterol Targets With Statin Therapy, New ESC-EAS Cholesterol Guidelines Say

Michael O'Riordan

August 27, 2016

News Daily News

ARISTOTLE Analysis: Don’t Shy Away From Standard Apixaban Dose in Certain High-Risk Patients

July 29, 2016

News Daily News

ISAR-TRIPLE Published: No Net Gain for 6 Weeks vs 6 Months of Triple Therapy

April 29, 2015

News Daily News

Since COURAGE, Little Change in Optimal Medical Therapy for Stable PCI Patients

May 10, 2011

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.